Reproxalap ( DrugBank: Reproxalap )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 160 | Congenital ichthyosis | 1 |
160. Congenital ichthyosis
Clinical trials : 42 / Drugs : 71 - (DrugBank : 21) / Drug target genes : 18 - Drug target pathways : 112
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03445650 (ClinicalTrials.gov) | July 18, 2018 | 14/2/2018 | RESET Trial - Part 1 (Followed by Reset Trial - Part 2) - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS) | A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of ADX-102 1% Topical Dermal Cream (Reproxalap) in Subjects With Sjögren-Larsson Syndrome (SLS) | Sjogren-Larsson Syndrome | Drug: ADX-102 1% Topical Dermal Cream (reproxalap);Drug: Vehicle of ADX-102 Topical Dermal Cream | Aldeyra Therapeutics, Inc. | NULL | Completed | 3 Years | N/A | All | 11 | Phase 3 | United States |